Treatment of Alzheimer's disease
Grant
US12576044B2
Kind: B2
Mar 17, 2026
Inventors
Paul A. Knepper
Abstract
Neurodegenerative diseases are treated by the co-administration to a subject of an effective amount of a stilbene, a flavonol, and a TLR4/MD2 receptor antagonist. A preferred stilbene is resveratrol, a preferred flavonol is quercetin, and a preferred TLR4/MD2 receptor antagonist is curcumin.
CPC Classifications
A61K 31/05
A61K 9/4858
A61K 31/352
A61K 31/485
A61K 45/06
A61P 7/02
A61P 27/06
A61P 25/28
A61P 17/02
Filing Date
2023-05-03
Application No.
18143001
Claims
7